Find clinical trials for Alzheimer's Disease in Paris, Île-de-France
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Alzheimer's Disease trials near Paris, Île-de-France, FRA:
efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...
Phase 2, Phase 3
Paris cedex 13, Paris, France and 38 other locations
To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...
Phase 2, Phase 3
Paris cedex 13, Paris, France and 37 other locations
versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...
Phase 2
Paris, France and 101 other locations
be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...
Phase 2
Paris, France and 168 other locations
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...
Phase 3
Paris cedex 10, Paris, France and 246 other locations
administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's...
Phase 2, Phase 3
Paris, France and 124 other locations
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (inclu...
Phase 2
Paris, France and 103 other locations
This proof-of-concept study will assess safety, tolerance, and efficacy of NanoLithium® NP03 in patients with mild-to-severe Alzheimer's Disease...
Phase 2
Paris, France and 7 other locations
A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's...
Phase 2
Paris, France and 91 other locations
study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's...
Phase 2
Paris, France and 183 other locations
Clinical trials
Research sites
Resources
Legal